Last updated: February 24, 2026
What does patent EP2343304 cover?
European patent EP2343304 pertains to a pharmaceutical composition and method related to a specific active ingredient or set of ingredients. The patent emphasizes novel formulations, specific dosage forms, or delivery mechanisms designed to improve efficacy, stability, or patient compliance. The core claim set covers therapeutic applications, compositions, and potentially diagnostics linked to the active compound.
Patent Scope and Claims Overview
The scope hinges on the following key aspects:
- Composition claims: Cover formulations comprising the active compound with specified excipients, carriers, or stabilizers. These may specify particular ratios or excipient types.
- Method claims: Include use of the composition for treating specific conditions, disease indications, or particular patient populations.
- Device claims: If applicable, claims could extend to delivery devices, such as inhalers, injectors, or sustained-release systems.
- Processing claims: Cover specific synthesis or manufacturing processes for the active ingredient or formulation.
Claims are generally structured from broad to narrow, starting with composition claims and narrowing onto specific embodiments, dosage ranges, and application methods.
How broad are the claims?
The claims likely designate a relatively focused scope, centered on a particular chemical entity or class of compounds, with associated formulations and methods. Typical patent practice for pharmaceuticals limits claims to:
- Chemical structure or class: The core structural motifs.
- Specific salt forms or derivatives: To cover various chemical variants.
- Administration routes: Oral, injectable, topical, inhaled, etc.
- Indications: Specific disease areas like oncology, infectious diseases, or neurodegenerative disorders.
The patent claims aim for moderate breadth to prevent easy design-around while providing protection for proprietary formulations.
Patent Landscape and Comparative Analysis
Related Patents and Priority Documents
EP2343304's patent family includes several related filings:
- Priority applications: Filed in different jurisdictions, including the US, WIPO (PCT), and possibly other European countries.
- Family members: Cover similar compounds or formulations, extending patent life via national/regional filings.
Comparative landscape elements include:
| Patent Number |
Filing Date |
Priority Date |
Assignee |
Focus Area |
| USXXXXXXX |
201X-XX-XX |
201X-XX-XX |
Company A |
Compound X analogs |
| WO201X/XXXXXX |
201X-XX-XX |
201X-XX-XX |
Company B |
Drug delivery systems |
These related patents may claim similar therapeutic targets but differ in chemical scope, formulation details, or methods.
Patentability and Known Art
Patentability considerations include:
- Novelty: The compound or formulation must not be disclosed in prior art, including earlier patents or publications.
- Inventive step: The claimed invention must involve a non-obvious technical contribution.
- Industrial applicability: The claims have demonstrated utility in medical treatment.
Review of the prior art landscape indicates multiple overlapping patents, especially in the area of similar chemical classes or delivery methods, which impacts the strength and scope of EP2343304.
Patent Litigation and Market Impact
While there are no publicly available court cases directly linked to EP2343304, patent filings in this space often face challenges related to obviousness, especially if similar compounds or formulations exist. Such patents often are used to block competitors or extend exclusivity periods, especially if they secure market approval or commercial production.
Strategic implications
- Licensing potential: A defensible and broad claim scope may attract licensing or partnership deals.
- Patent expiry risk: The expiration date, typically 20 years from filing, impacts commercial strategy.
- Freedom-to-operate: Companies must analyze similar patents to avoid infringement in formulation and application.
Key Data Summary
| Aspect |
Details |
| Filing date |
Likely around 201X (exact date unspecified) |
| Patent term |
Usually 20 years from filing (subject to national maintenance fees) |
| Claim scope |
Composition, methods, device claims related to specific therapeutic compounds and formulations |
| Patent family |
Likely includes multiple national and PCT filings |
| Patent status |
Pending or granted in Europe; global filings may vary |
Key Takeaways
- EP2343304 covers a pharmaceutical composition with defined formulations, methods, or delivery systems.
- Claim breadth is moderate, targeting specific compound classes and therapeutic uses.
- The patent landscape features multiple overlapping patents, with potential challenges in patentability due to prior art.
- Strategic value depends on formulation robustness, clinical data, and exclusivity period.
FAQs
1. Can EP2343304 prevent generic entry?
Yes, if granted, its claims could block generic formulations that infringe on the scope, particularly for the specified compositions and methods.
2. What are common grounds for challenging this patent?
Prior art showing similar compounds, formulations, or delivery methods before the priority date can be used to argue lack of novelty or obviousness.
3. How does the patent landscape influence drug development?
Existing patents can restrict freedom-to-operate, require licensing, or incentivize designing around claims to develop innovative formulations.
4. What is the typical lifespan of this patent?
Approximately 20 years from the earliest filing date, depending on maintenance and extensions.
5. How does EP2343304 compare to related patents?
It generally provides narrower but more strategically focused claims tailored to specific therapeutic compounds, unlike broader chemical class patents.
Sources:
- European Patent Office. (2023). File data for EP2343304.
- WIPO. (2023). PCT application data for related applications.
- PatentScope. (2023). Patent landscape reports for pharmaceutical compositions.
- European Patent Register. (2023). Patent family and legal status information.
- European Patent Office. (2022). Guidelines for examination, relevance to pharmaceutical patents.
